The price-to-earnings ratio for Royalty Pharma stock stands at 11.32 as of May 2, 2024. This is based on the current EPS of $2.54 and the stock price of $28.76 per share. A decrease of 76% has been recorded in the PE ratio compared to the average of 46.3 of the last four quarters.
Over the last four years, the average PE ratio of Royalty Pharma has been 55.04. The current 11.32 P/E ratio is 79% lower than the historical average. In the past four years, RPRX's PE ratio peaked in the Dec 2022 quarter at 395.2, with a price of $39.52 and an EPS of $0.1. The Sep 2020 quarter marked the lowest point at 7, with a price of $42.07 and an EPS of N/A.
Maximum annual increase: 1,377.94% in 2022
Maximum annual decrease: -97.2% in 2023
| Year | PE ratio | Change |
|---|---|---|
| 2023 | 11.06 | -97.2% |
| 2022 | 395.2 | 1,377.94% |
| 2021 | 26.74 | -29.48% |
| 2020 | 37.92 | N/A |
| 2019 | N/A | N/A |
| 2018 | N/A | N/A |
| 2017 | N/A | N/A |
Currently, RPRX's PE ratio is lower than the 3-year average.
RPRX's PE ratio stands lower than its peer stocks LLY and ABT.
| Stock name | PE ratio | Market cap |
|---|---|---|
| RPRX Royalty Pharma plc | 11.1 | $16.85B |
| ABT Abbott Laboratories | 32.73 | $183.91B |
| ANIP Ani Pharmaceuticals Inc | 77.62 | $1.41B |
| LLY ELI LILLY & Co | 107.77 | $698.56B |
The price to earnings ratio for RPRX stock as of May 2, 2024, stands at 11.32.
The 3-year average price to earnings ratio for RPRX stock is 67.66.
The highest quarterly PE ratio in the last four years has been 395.2 and it was in the Dec 2022 quarter.
RPRX's current price to earnings ratio is 79% below its 4-year historical average.
The P/E ratio is obtained by dividing the latest price of a stock by its trailing twelve months EPS. As of today (May 2, 2024), Royalty Pharma's stock price is $28.76. The earnings per share for the trailing twelve months (TTM) ending Dec 2023 is $2.54. Therefore, Royalty Pharma's PE ratio for today is 11.32. PE RATIO(11.32) = STOCK PRICE($28.76) / TTM EPS($2.54)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.